CRNAs and Medication-Assisted Treatment (MAT)
The Substance Use Disorder Prevention that Promotes Opioid Recovery and Treatment (SUPPORT) Act for Patients Communities Act was enacted into law on October 24, 2018. Within section 3201, this Act expands earlier legislation in the 2016 Comprehensive Addiction and Recovery Act (CARA) to include Certified Registered Nurse Anesthetists (CRNAs) among providers able to prescribe medication-assisted treatment (MAT) to individuals suffering from opioid addiction.
- Currently waiting for the MAT waiver application to be available for CRNAs, see more info below.
- AANA letter to HHS: AANA Supports Increased Patient Assess to Safe, Responsible Use of MAT, June 25, 2019
- AANA Opioid Crisis Resources
- AANA Press Release, October 24, 2018
AANA Position Statement and Considerations
The AANA supports increased patient access to safe, responsible use of MAT for the comprehensive treatment of substance and opioid use disorder. Please review the position statement and considerations document Certified Registered Nurse Anesthetists Medication-Assisted Treatment for more information on MAT, a CRNA's ethical obligation and professional responsibility, prescriptive authority limitation, and steps for obtaining the MAT waiver.
Anesthesia Considerations for Patients on MAT, in Active State of Opioid Use Disorder, or Opioid Therapy
- AANA Practice Considerations: Analgesia and Anesthesia for the Substance Use Disorder Patient (2019)
- AANA Journal article: The Opioid Crisis and the Certified Registered Nurse Anesthetists: Caring for Patients receiving Medication-Assisted Treatment June 2019 Guest Editorial
- American Society for Enhanced Recovery and Perioperative Quality Initiative Joint Consensus Statement on Perioperative Management of Patients on Preoperative Opioid Therapy, Anesthesia Analgesia
MAT Waiver Application and Related Info
The waiver application for CRNAs to prescribe buprenorphine as medication-assisted therapy is not available yet on the SAMHSA website. Please email email@example.com with subject “MAT” if you’d like email notice when the waiver is accessible. Here is some background and related resources on the topic.
Substance Abuse and Mental Health Administration (SAMHSA)
- All About Medication-Assisted Treatment (MAT)
- Current related Legislation, Regulations, and Guidelines
- Buprenorphine Treatment Practitioner Locator
- Buprenorphine info center 866-287-2728
U.S. Food & Drug Administration (FDA)
- FDA announces public health emergency prioritization of ANDAs for drug products for the emergency treatment of opioid overdose
- Statement from Commissioner Scott Gottlieb, M.D., on 2019 policy and regulatory agenda for continued action to forcefully address the tragic epidemic of opioid abuse, February 26, 2019
- Statement from Commissioner Scott Gottlieb, M.D., on new regulatory authorities as part of the newly enacted SUPPORT for Patients and Communities Act, October 24, 2018
U.S. Department of Health & Human Services (HHS) Office of the Surgeon General
National Academies of Sciences, Engineering and Medicine
National Conference of State Legislatures (NCSL)
- NCSL Scope of Practice Policy map indicating the number of nurse practitioners (NPs) and physician assistants (PAs) prescribing buprenorphine by state, based on SAMSHA waivers issued: Behavioral Health Providers Overview
National Institutes of Health (NIH)
- Mission: To advance excellence in nursing care for the prevention and treatment of addictions for diverse populations across all practice setting through advocacy, collaboration, education, research and policy development.
- Addiction Nurses Save Lives